Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.
about
The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis.Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
P2860
Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Safety and clinical responses ...... months of etanercept therapy.
@en
type
label
Safety and clinical responses ...... months of etanercept therapy.
@en
prefLabel
Safety and clinical responses ...... months of etanercept therapy.
@en
P2093
P2860
P1476
Safety and clinical responses ...... e months of etanercept therapy
@en
P2093
Dae-Hyun Yoo
Hee-Jin Park
Jae-Bum Jun
Tae-Hwan Kim
Tae-Jong Kim
Wan-Sik Uhm
P2860
P304
P356
10.3346/JKMS.2008.23.5.852
P577
2008-10-01T00:00:00Z